First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial-Reference-Cited by-同舟云学术

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Published:2010-12 Issue:9757 Volume:376 Page:1989-1999
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Morgan Gareth J,Davies Faith E,Gregory Walter M,Cocks Kim,Bell Sue E,Szubert Alex J,Navarro-Coy Nuria,Drayson Mark T,Owen Roger G,Feyler Sylvia,Ashcroft A John,Ross Fiona,Byrne Jennifer,Roddie Huw,Rudin Claudius,Cook Gordon,Jackson Graham H,Child J Anthony

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Treatment of multiple myeloma: a comprehensive review;Kyle;Clin Lymphoma Myeloma,2009

2. Bone complications in multiple myeloma;Berenson;Cancer Biol Ther,2006

3. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network;Terpos;Ann Oncol,2009

4. Bisphosphonates: preclinical review;Green;Oncologist,2004

5. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment;Corso;Hematology,2005

Cited by 498 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis;Hematology Reports;2024-08-06

3. Deciphering the genetics and mechanisms of predisposition to multiple myeloma;Nature Communications;2024-08-05

4. Incidence and prevention of skeletal‐related events in multiple myeloma patients: A population‐based real‐world experience;eJHaem;2024-05-29

5. Clinical status of established MRONJ in oncology patients continuing bone-modifying agents;British Dental Journal;2024-05-10